Form 4: Oramed COO & CBO Reports Significant Equity Grants

Oramed Pharmaceuticals COO & CBO Joshua Hexter reported the acquisition of over 200,000 Restricted Stock Units and 19,000 Performance Stock Units.

Summary

• Joshua Hexter, Oramed Pharmaceuticals Inc.'s COO & CBO, reported the acquisition of 97,328 Restricted Stock Units (RSUs) on December 31, 2025, which vested in full on January 1, 2026.
• An additional 115,000 RSUs were acquired on December 31, 2025, set to vest in quarterly installments over a three-year period starting January 1, 2026.
• Hexter also acquired 19,000 Performance Stock Units (PSUs) on December 31, 2025, which vest upon the achievement of either a specified stock price or applicable performance criteria.
• Following these transactions, Joshua Hexter beneficially owns 1,045,495 shares of Common Stock directly and 19,000 derivative Performance Stock Units directly.
• Each RSU and PSU represents the right to receive one share of Oramed's common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates strong executive alignment with shareholder interests through significant equity grants, including performance-based incentives. However, it does not reflect operational or financial performance.

Positives

• Significant equity grants to a key executive, Joshua Hexter, aligning his interests with those of shareholders.
• The grants include both time-based RSUs and performance-based PSUs, incentivizing long-term performance and stock price appreciation.

Future Outlook

The future outlook includes the vesting of 115,000 RSUs in quarterly installments over a three-year period starting January 1, 2026, and the potential vesting of 19,000 PSUs upon the achievement of specified stock price or performance criteria.

Industry Context

This filing reflects a standard practice in the biotechnology and pharmaceutical industry where executive compensation packages often include significant equity components like RSUs and PSUs to attract, retain, and incentivize key talent, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) for executive compensation is a common practice across the pharmaceutical and biotech sectors, similar to compensation structures seen at companies like Pfizer, Moderna, or Johnson & Johnson, which aim to link executive rewards directly to company performance and shareholder returns.
• The vesting schedules, including immediate vesting for some RSUs and multi-year, performance-based vesting for others, are consistent with industry benchmarks designed to ensure long-term commitment and incentivize strategic achievements.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of executive interests with long-term shareholder value through equity compensation.
• Employees: May signal stability and a commitment to executive retention, potentially boosting morale.

Next Steps

• Continued vesting of 115,000 RSUs in quarterly installments over the next three years, starting January 1, 2026.
• Monitoring the achievement of specified stock price or performance criteria for the vesting of 19,000 PSUs.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to a key executive, which is a standard practice to align management incentives with shareholder value. While positive for corporate governance and executive retention, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation based solely on this report. Investors should continue to hold and monitor the company's core business fundamentals.

Keywords

Oramed Pharmaceuticals, ORMP, Joshua Hexter, Restricted Stock Units, Performance Stock Units, Equity Compensation, Insider Ownership, Executive Compensation, SEC Form 4